ONS ONCC CHEMOTHERAPY 2026
CLINICAL SCRIPT SOLVED
QUESTIONS VERIFIED ANSWERS A+
◉ A comprehensive geriatric assessment (CGA) is a multidisciplinary
evaluation to assess life expectancy and risk of morbidity and mortality
in the older patient. This assessment tool would evaluate and include the
following areas: functional status, socioeconomic issues, psychosocial
distress, comorbidities, cognitive function, nutritional status,
polypharmacy, and a medication review (NCCN Older Adult Oncology
Guidelines, version 1.2015)..
Answer: Due to Mrs. Turner's age and comorbidities, her oncologist
performs a comprehensive geriatric assessment. You know that this
assessment covers all but which of the following:
◉ 65.
Answer: The NCCN Older Adult Oncology Guidelines (version 1.2015)
provides information on what is included in a comprehensive geriatric
assessment. Currently, more than 60% of cancers in the United States
occur in people age ______and older and as the oncology world ages,
nearly half (46%) of cancer survivors are 70 years of age or older
◉ Two of the agents (docetaxel and carboplatin) that Mrs. Turner will
receive are categorized as irritants. Docetaxel can cause a significant
reaction if it extravasates. It can lead to edema, erythema, occasional
pain and blister formation (ONS Chemo/Bio guidelines, 2014). That is
the most likely reason that Mrs. Turner was given a port for her
treatments. Some patients will receive their treatments through a
peripheral IV without incident. Just because they are intravenous agents
,does not mean that a port is required and needing a port has nothing to
do with her being older in age. Since none of these agents are vesicants,
they likely could have been given safely via peripheral route but having
a port placed is OK as well..
Answer: What is your best explanation for why Mrs. Turner was given a
port to receive her chemotherapy?
◉ Irrirtants.
Answer: _____________can cause inflammation, pain, and burning but
rarely cause tissue necrosis comparable to a vesicant (unless a large
amount or a very high concentration of the irritant is extravasated).
◉ Vesicants.
Answer: _____________can cause blistering and significant pain and
tissue damage and destruction, leading to tissue death.
◉ Non-DNA-binding solutions remain in the local area of the
extravasation, which improves the possibility of drug deactivation.
DNA-binding agents attach to DNA nucleic acids, causing the
antagonist to be ingested cellularly, leading to progressive tissue
destruction.
Answer: A further classification of an antineoplastic agent's potential to
cause damage is whether its mechanism of action includes DNA
binding.
◉ Bendamustinea
, Dactinomycin
Daunorubicin
Doxorubicin
Epirubicin
Idarubicin
Mechlorethamine
Mitomycin.
Answer: DNA Binding Irritants
◉ Amsacrine
Paclitaxel
Vinblastine
Vincristine
Vindesine
Vinorelbine.
Answer: DNA Nonbinding vessicants
◉ Sodium thiosulfate
Inject 2 ml of sodium thiosulfate for each milligram of
mechlorethamine extravasated.
Inject subcutaneously into extravasation site using a 25
gauge or smaller needle (change needle with each injection).
CLINICAL SCRIPT SOLVED
QUESTIONS VERIFIED ANSWERS A+
◉ A comprehensive geriatric assessment (CGA) is a multidisciplinary
evaluation to assess life expectancy and risk of morbidity and mortality
in the older patient. This assessment tool would evaluate and include the
following areas: functional status, socioeconomic issues, psychosocial
distress, comorbidities, cognitive function, nutritional status,
polypharmacy, and a medication review (NCCN Older Adult Oncology
Guidelines, version 1.2015)..
Answer: Due to Mrs. Turner's age and comorbidities, her oncologist
performs a comprehensive geriatric assessment. You know that this
assessment covers all but which of the following:
◉ 65.
Answer: The NCCN Older Adult Oncology Guidelines (version 1.2015)
provides information on what is included in a comprehensive geriatric
assessment. Currently, more than 60% of cancers in the United States
occur in people age ______and older and as the oncology world ages,
nearly half (46%) of cancer survivors are 70 years of age or older
◉ Two of the agents (docetaxel and carboplatin) that Mrs. Turner will
receive are categorized as irritants. Docetaxel can cause a significant
reaction if it extravasates. It can lead to edema, erythema, occasional
pain and blister formation (ONS Chemo/Bio guidelines, 2014). That is
the most likely reason that Mrs. Turner was given a port for her
treatments. Some patients will receive their treatments through a
peripheral IV without incident. Just because they are intravenous agents
,does not mean that a port is required and needing a port has nothing to
do with her being older in age. Since none of these agents are vesicants,
they likely could have been given safely via peripheral route but having
a port placed is OK as well..
Answer: What is your best explanation for why Mrs. Turner was given a
port to receive her chemotherapy?
◉ Irrirtants.
Answer: _____________can cause inflammation, pain, and burning but
rarely cause tissue necrosis comparable to a vesicant (unless a large
amount or a very high concentration of the irritant is extravasated).
◉ Vesicants.
Answer: _____________can cause blistering and significant pain and
tissue damage and destruction, leading to tissue death.
◉ Non-DNA-binding solutions remain in the local area of the
extravasation, which improves the possibility of drug deactivation.
DNA-binding agents attach to DNA nucleic acids, causing the
antagonist to be ingested cellularly, leading to progressive tissue
destruction.
Answer: A further classification of an antineoplastic agent's potential to
cause damage is whether its mechanism of action includes DNA
binding.
◉ Bendamustinea
, Dactinomycin
Daunorubicin
Doxorubicin
Epirubicin
Idarubicin
Mechlorethamine
Mitomycin.
Answer: DNA Binding Irritants
◉ Amsacrine
Paclitaxel
Vinblastine
Vincristine
Vindesine
Vinorelbine.
Answer: DNA Nonbinding vessicants
◉ Sodium thiosulfate
Inject 2 ml of sodium thiosulfate for each milligram of
mechlorethamine extravasated.
Inject subcutaneously into extravasation site using a 25
gauge or smaller needle (change needle with each injection).
